Newron Pharmaceuticals (NWPHF) Stock Price, News & Analysis

Company Overview

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on developing treatments for diseases of the central nervous system. The company’s research activities have centered on neurological and psychiatric disorders, including Parkinson’s disease, schizophrenia and other conditions with significant unmet medical needs.

Newron’s best-known product is Xadago (safinamide), an oral treatment used as add-on therapy for Parkinson’s disease in patients experiencing motor fluctuations. The product was developed by Newron and is commercialized in various markets through licensing and commercial partnerships, including with Zambon.

The company is also advancing evenamide, an investigational treatment being studied for schizophrenia, including difficult-to-treat forms of the disorder. Newron has historically pursued a partnership-based development and commercialization strategy, working with pharmaceutical companies to support the regulatory approval and distribution of its products across international markets.

Newron traces its origins to Italy and operates as an international pharmaceutical company with activities spanning Europe and other global markets. Stefan Weber serves as chief executive officer, providing leadership as the company focuses on clinical development, regulatory programs and commercial partnerships in central nervous system medicine.

Key Stats

• Today's Range: $20.00 to $20.00
• 50-Day Range: $20.00 to $20.00
• 52-Week Range: $9.10 to $20.00
• Volume: N/A
• Average Volume: 600 shs
• Market Capitalization: $357 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:NWPHF
• CIK: N/A
• Web: www.newron.com
• Phone: (902) 610-3461
• Fax: 39-02-6103-4654
• Employees: 22
• Year Founded: 1999

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $6.82 million
• Price / Sales: 52.35
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.21 per share
• Price / Book: 95.24

Miscellaneous

• Outstanding Shares: 17,850,000
• Free Float: N/A
• Market Cap: $357 million
• Optionable: Not Optionable
• Beta: 0.53